Dr. Reddy's Laboratories has halted commercial shipments of its generic semaglutide after a quality problem with the active pharmaceutical ingredient was discovered. The move sent the stock down nearly 6% and prompted Torrent Pharmaceuticals to issue a voluntary recall of certain pen batches.
Hyderabad‑based pharmaceutical giant Dr. Reddy's Laboratories announced on July 9 that it is suspending commercial supplies of its generic semaglutide. The suspension follows the detection of a quality deviation in the active pharmaceutical ingredient (API), rendering some batches out of specification. The company expects fresh dispatches only by late October or early November after corrective actions are validated.
Why semaglutide matters
Semaglutide is the core molecule behind Novo Nordisk’s blockbuster diabetes and obesity drugs Wegovy and Ozempic. After the patent expired in March 2026, several Indian manufacturers, led by Dr. Reddy’s, rushed to launch generic versions to capture a fast‑growing market. The firm had projected sales of 12 million injection pens for the fiscal year, positioning itself as a key player in India’s obesity‑treatment landscape.
Market reaction and recall
The announcement triggered a sharp decline on the Bombay Stock Exchange, with Dr. Reddy’s shares falling about 5.85% to close at ₹1,269.80. In parallel, Torrent Pharmaceuticals disclosed a voluntary recall of select batches of the Semalix disposable pens, acting on Dr. Reddy’s instruction. Torrent clarified that the recall concerns only one batch in India and does not affect product safety or supply elsewhere.
Company response and next steps
CEO Erez Israeli told analysts that an unknown impurity surfaced during a scale‑up of production, prompting the halt. A thorough root‑cause investigation is underway, and the manufacturing process will be upgraded before any commercial release resumes. The firm emphasized that existing market‑available products remain safe and that oral semaglutide tablets, sourced from a different API provider, are unaffected.
Implications for the Indian pharma sector
With a three‑month supply gap, Dr. Reddy’s is unlikely to meet its 12 million‑pen target, potentially selling only 6‑7 million units in Q3‑Q4 FY27. The episode underlines the critical importance of stringent quality controls during rapid scale‑up, especially for high‑demand molecules that address obesity—a growing public‑health challenge in India. Competitors may seize the opportunity, reshaping market dynamics and pricing structures.
